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Abstract
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Objective.—Knowledge of one’s gene status for adult onset conditions provides opportunity to
make advance end-of-life (EOL) plans. The purposes of these analyses were to: 1) determine the
prevalence of EOL plans, including advance directives (ADs) among persons across three stages of
Huntington disease (HD); and 2) examine factors associated with having ADs in this sample.
Methods.—Data are from 503 participants in the Huntington Disease Quality of Life study.
Participants completed an online health-related quality of life survey that included questions
regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL
planning by HD stage. Bivariate analysis and logistic regression were used to identify variables
associated with having ADs.

Author Manuscript

Results.—38.2% of participants stated they had ADs and fewer than half had other EOL plans.
Being older, increased HD stage, more years of education, lower anxiety, more swallowing
symptoms, and higher meaning and purpose were associated with having ADs.
Conclusion.—The prevalence of ADs in our sample is comparable to the general US population,
but surprisingly low considering the severity and long disease course of HD.
Practice Implications.—Health care providers should develop specific interventions early in
the disease process to increase ADs in this population.

Correspondence to: Nancy R. Downing, Texas A&M College of Nursing, 8447 State Highway 47, Bryan, TX, 77807, USA. Tel:
979-436-0157; Fax: 979-436-0098. downing@tamhsc.edu.
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Huntington disease (HD) is a devastating neurodegenerative disease for which there is
palliative treatment, but no cure. The disease is caused by an autosomal dominant
trinucleotide CAG repeat expansion on the HTT gene. Symptoms typically begin in middle
age, and include progressive decline in cognitive, behavioral, motor, and day-to-day
functioning [1] that significantly impact health-related quality of life (HRQOL) [2, 3].
Progression to dementia is inexorable; death occurs approximately 17–20 years following
motor diagnosis [1]. Presymptomatic genetic testing has been available since the discovery
of the HTT gene mutation in 1993 [4]. If a patient does not undergo presymptomatic genetic
testing, diagnoses are made based on consistent family history with typical motor signs (e.g.
chorea) or confirmation by genetic testing [5]. One of the benefits of knowing one’s gene
status for an adult onset disease, especially one that involves dementia, is the ability to make
advance end of life (EOL) decisions while one still has the cognitive capacity [6].

Author Manuscript

Advance directives (ADs), including living wills, health care powers of attorney, or health
care directives, are legal documents that state an individual’s preferences for medical
treatment and to appoint a surrogate to make decisions on their behalf if they become
incapacitated [7]. Advance directives are effective in decreasing unwanted hospitalization
and unwanted life-sustaining treatment, and increasing the use of palliative and hospice care
[8]. Since HD affects decision-making capacity in later stages, it is imperative that EOL
discussions occur early in the disease course [9]. A working group on EOL planning needs
for people with HD funded by the Robert Wood Johnson Foundation recommended
healthcare providers educate persons with HD on the need to develop and complete ADs
[10].

Author Manuscript

Despite a recognized need, the prevalence of ADs among persons with HD in the US is not
known. People usually have prior knowledge of their HD risk because they have affected
family members or have undergone HD genetic testing. Knowledge of gene status for adult
onset conditions provides the opportunity to make advance EOL plans [6]. People with HD
might be more likely than the general population to have ADs since people with chronic
diseases in the general US population are more likely to have ADs than those without
chronic disease [11]. The purposes of these analyses were to: 1) examine the prevalence of
ADs and other EOL plans in a large sample of people at three stages of HD; and 2) examine
the demographic, clinical and self-reported HRQOL factors associated with having ADs in
this sample.
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Methods
Setting/Sample
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Data for this analysis come from the first phase of the Huntington Disease Quality of Life
(HDQLIFE) Study. The purpose of the HDQLIFE study is to develop computer adaptive
tests (CATs) and short forms (SF) to assess patient-reported HRQOL for persons with HD
[12–15]. Individuals with prodromal or manifest HD (N=503) 18 years and older and able to
read and understand English participated in the first phase of the study (12/19/2012–
12/14/2014). Participants were recruited at a variety of specialized treatment centers across
the US (University of Michigan, University of Iowa, University of California - Los Angeles,
Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson’s
Center, Washington University at St. Louis, University of California – San Francisco, and
the Cleveland Clinic), from the PREDICT-HD study [16], the National Research Roster for
Huntington’s Disease [17], and articles and advertisements in HD newsletters and websites.
This study was approved by all participating institutions’ human subjects research boards
and all participants provided informed consent.

Author Manuscript

There were 505 participants in the HDQLIFE study. Data regarding HD stage was missing
for two participants. Thus, analyses that included comparisons between HD stage included
503 participants stratified into three HD stages: prodromal (n=197), early (n=193), and late
(n=113). Prodromal stage included individuals who did not have a clinical diagnosis of HD
but had a confirmed CAG repeat ≥36, meaning they will eventually develop HD if they have
a normal lifespan; manifest HD participants (n=308) had a neurologist-confirmed HD
clinical diagnosis or received a ≥99% confidence rating on the motor component of the
Unified Huntington’s Disease Rating Scale (UHDRS), indicating unequivocal signs of HD.
Staging of HD for participants with manifest HD was classified according to the UHDRS
Total Functional Capacity (TFC) scale [18], a clinician-administered scale evaluating day-today function regarding occupation, finances, domestic chores, activities of daily living, and
care level. Scores range from 0 (low functioning) to 13 (high functioning). Participants were
classified as early stage (7–13) or late stage HD (0–6).
Assessments

Author Manuscript

Participants completed the HDQLIFE protocol, including questions regarding EOL
planning, including ADs, living wills, healthcare power of attorney, resuscitation preference,
conversations about death and dying, location of death preference, nursing home care,
palliative care, and hospice care. All participants were asked to answer questions about all
these items. Due to confusion regarding the definitions of these terms in the general public
that might be relevant in this study, the focus of our analysis was on comparison of
participants with and without ADs. Information regarding ADs was assessed by a single
item, “Advance directive (also known as a Living will).” Participants were instructed to
choose the response that best described where they stood regarding ADs: “I have not thought
about getting an advance directive;” “I have thought about getting an advance directive;” “I
have taken steps to obtain an advance directive;” and “I have an advance directive.” Similar
response choices were provided for other items.
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Participants also completed newly developed self-report assessments for the presence of HD
symptoms, concerns about HD, impact of symptoms, and concerns on HRQOL. We used SF
versions of these measures that were created using item response analyses: HDQLIFE
Speech Difficulties SF [15], HDQLIFE Swallowing Difficulties SF [15], HDQLIFE Chorea
SF [13], HDQLIFE Concern with Death & Dying SF, and HDQLIFE Meaning & Purpose
SF [12]. All HDQLIFE measures generate T scores on a T-metric relative to other
individuals with HD. T-scores are standardized scores with mean of 50 and standard
deviation of 10; higher scores indicate more of the construct being measured (e.g., more
speech difficulty, or greater meaning and purpose). Participants also completed the PatientReported Outcomes Measurement Information System (PROMIS) Anxiety SF [19]; higher
scores indicate more anxiety and is scored on a T-metric with the general population as
referent.

Author Manuscript

Trained clinicians administered the UHDRS Total Motor Score (TMS) in person.
Participants completed patient-reported outcome (PRO) measures through PROMIS
Assessment Center (https://www.assessmentcenter.net) at a designated computer or tablet
during the study visit or were asked to complete it within two weeks of the study visit.
Participants and those assisting them were instructed that responses were to come directly
from participants (i.e., assistance was limited to logging into the online study platform,
reading questions aloud, and/or clicking response options, when needed).
Data Analysis

Author Manuscript
Author Manuscript

Participants were classified as “with ADs” when participants selected the response option “I
have an advance directive;” all other responses to that question were classified as “without
ADs.” We calculated descriptive statistics for demographic variables (age, gender, race,
ethnicity, marital status, years of education), and scores on HDQLIFE and PROMIS
measures. Analyses of variance (ANOVA) were used to compare demographic differences
between prodromal, early, and late stages. Sociodemographic and clinical characteristics of
participants with and without ADs were compared using chi-square for categorical data:
gender, race, marital status, and HD stage; independent t-tests were conducted to compare
continuous data: age, years of education, and self-report SF (HDQLIFE Chorea, HDQLIFE
Speech, HDQLIFE Swallowing, HDQLIFE Concern with Death & Dying, HDQLIFE
Meaning & Purpose, and PROMIS Anxiety). We used an alpha of .05 for all t-tests. We used
Bonferroni adjusted alpha levels for the variables groups demographics (.05/5 variables = .
01) and HDQLIFE/PROMIS measures (.05/6 variables = .008). We did not correct for all
variables together (.05/12 = .004) because this is the first known analysis on this topic and
we did not want to miss potentially important differences that could be further examined in
future studies.
In the logistic regression model, variables that were significantly different (p < 0.05)
between participants with and without ADs in chi-square and t-tests were included to
determine which factors independently increased odds of having ADs: age, HD stage,
education, HDQLIFE Concern for Death & Dying, HDQLIFE Meaning & Purpose, and
PROMIS Anxiety. Age and years of education were entered as continuous variables and T
scores were used for HDQLIFE and PROMIS Anxiety. HDQLIFE Swallowing was not
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included because the difference between those with ADs (53.83) and without ADs (52.78)
was unlikely to be clinically meaningful. Although not significant in t-tests, HDQLIFE
Concern for Death & Dying was included in the model because this psychological variable
might impact whether a person has ADs.

Results

Author Manuscript

Participant demographics are shown in Table 1. The age range of participants was 18–81,
mean 49.04 years. Most participants were White (96%) and not Hispanic (93.7%). There
were some notable differences in ANOVA comparisons between prodromal vs. early and
prodromal vs. late stage groups on some variables: There were differences in age, F (2, 500)
= 44.377, p < .001, and years of education, F (2,498) = 15.415, p < .001, with participants in
the prodromal stage being younger and having more years of education than those in the
early and those in the late stage. More prodromal stage participants were married compared
to early stage, X2 (2, 502) = 8.12, p = .017.
Overall, 38.2% of participants reported they had ADs. Frequencies and percentages for ADs
and associated EOL planning are presented in Table 2 for each HD stage. In general, higher
percentages of participants in the late stage had ADs and other EOL plans.
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Chi-square results (Table 3) indicated significant differences between participants with and
without ADs for HD stage, X2 (2, n=503) = 9.01. Participants in late stage HD were more
likely to have ADs than those in prodromal or early stage HD. In t-test analyses (Table 3),
there were significant differences between participants with and without AD based on age,
t(503) = 8.63, p = <0.001; years of education, t(501) = −2.89, p=0.004; and HDQLIFE
Meaning & Purpose, t(493) = 2.92, p =0.004. Participants were more likely to have ADs if
they were older, had more years of education, and higher scores on HDQLIFE Meaning and
Purpose and HDQLIFE Swallowing, and lower scores on PROMIS Anxiety, although
Swallowing and Anxiety were not significant after correcting for multiple comparisons.
The multivariable logistic regression model explained 72.4% of the variance in predicting
whether a participant had ADs (Table 4). For each year of age, participants had 6% higher
odds of having ADs (odds ratio [OR] 1.06; 95% CI: 1.03, 1.08). Participants in the late stage
had almost three times higher odds of having ADs than the prodromal stage (OR 2.87, 95%
CI: 1.35, 6.14). Each year of education increased the odds of having ADs by 12% (OR 1.12,
95% CI: 1.02, 1.22). Early stage HD, HDQLIFE Concern for Death & Dying, HDQLIFE
Meaning & Purpose, and PROMIS Anxiety were not associated with higher odds of having
ADs.

Author Manuscript

Discussion
Huntington disease is a devastating disease that causes dementia and premature death.
People usually have many years to engage in EOL planning since the disease course spans
up to 20 years. We report data on the prevalence of ADs among a large sample of people
with HD in the US. Among the 503 participants in this analysis, 38.2% responded they had
ADs. This exceeds 31.3% of participants in a study of persons with HD in the Netherlands
[9], and 26.3% of people in the general US population [11]; however, it is lower than 47.3%
Am J Hosp Palliat Care. Author manuscript; available in PMC 2019 March 01.
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of participants over 60 in the US with two or more chronic conditions [20]. Considering the
severity of HD and its association with premature mortality, it is surprising only 38.2% of
participants had ADs.
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Older age has consistently been associated with having ADs in prior studies, as it was in
ours [9, 11, 20]. Our sample is relatively young (mean age = 49.04). When age is
considered, prevalence of ADs may be higher than among persons of similar ages without
HD. For example, in a study examining prevalence of ADs in the general population [11],
18.2% of participants ages 18–54 had ADs. In that light, 38.2% of participants in our study
with ADs appears relatively high. On the other hand, it is reasonable to assume that people
who know they face significant premature morbidity and death would have even higher
prevalence of ADs. Self-reported HD symptoms, including the hallmark symptom chorea,
were not associated with increased ADs in our study. Having more self-reported swallowing
symptoms was associated with having ADs in bivariate analyses, but the difference in
symptoms between those with and without ADs was very small and was significant after
correcting for multiple comparisons. There are some previously documented phenomena in
HD that might explain why prevalence of ADs was not as high as expected. For example,
decreased awareness of disease symptoms can occur in HD [21], and a tendency for persons
with HD to normalize symptoms [22]. While participants in late stage HD were almost three
times more likely than participants in the prodromal stage to have ADs, this could be related
more to age than presence of HD symptoms. Our findings suggest that persons with the HD
gene mutation are similar to those without HD with regard to EOL planning, despite
knowing more about their potential fate. The HDQLIFE study was not designed specifically
to examine this issue, however; thus, it is possible that other designs might better reveal the
motivations of persons with HD to make EOL plans.
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Participants with late stage HD in our study might have being diagnosed based on family
history and HD symptoms and not have had presymptomatic testing, either by choice or
because presymptomatic testing was not available before they developed symptoms. People
who get tested presymptomatically might be different from people who learn their gene
status through clinical diagnosis. In our study, participants in the prodromal stage had more
years of education than those in early and late stage HD, and more years of education
slightly increased the odds of having ADs. Higher education level has previously been
associated with having EOL plans in both HD and non HD samples [9, 11, 23–25]. The
relationship between education and having ADs might be mediated by literacy [23]. The use
of jargon, including multiple terms referring to ADs, might not clearly describe the intent
and usefulness of ADs to patients with lower literacy.

Author Manuscript

Participants in our study with higher self-reported scores on the PROMIS Anxiety SF were
less likely to have ADs in the bivariate analysis, although it was not significant after
correcting for multiple comparisons and it was not a predictor of having ADs in the logistic
regression model. In our study, HDLIFE Concern for Death & Dying was not significantly
associated with having ADs. Fear of death, anxiety and concern might, in fact, lead people
to avoid EOL planning in an effort to avoid increasing anxiety [26]. Therefore, it would still
be important to assess for anxiety, especially disease- and death-related anxiety, in future
studies.
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A potential benefit of presymptomatic HD genetic testing is the ability to plan for the future
[27, 28]. Participants in the prodromal stage in our study had undergone presymptomatic HD
genetic testing, yet had the lowest prevalence of ADs and other EOL plans in our sample.
Thus, genetic testing did not appear to strongly impact making EOL planning in the
prodromal stage. However, we cannot exclude that many of these participants will make
EOL plans while still cognitively able to do so.

Author Manuscript

Our study has some limitations that might impact generalizability of our findings. Race and
ethnicity are limitations because the vast majority of persons with HD in the US are of
European descent and non-Hispanic; prevalence rates are higher in North America, Europe
and Australia, compared to Asia [34]. Advance directives, living will, and other EOL
terminology such as palliative care were not defined in the HDQLIFE online survey. Given
that literacy is an identified barrier to ADs [23], participants might have responded without
having a clear understanding of these terms. Participants were encouraged to answer all
questions but were not forced to answer items. We did not include a response option to
indicate when participants did not understand a question. In the future, we could consider
defining these terms.
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Our sample included more participants in prodromal and early stages than late stage. This is
understandable, as decreased cognitive ability in later stages of HD could preclude capacity
to provide informed consent. Participants in the prodromal stage in our study might not be
representative of most people at risk for HD because they had independently undergone
presymptomatic HD testing while the uptake of presymptomatic genetic testing for HD is
estimated to be under 20% [35]. Many participants were recruited from sites that have HD
Centers of Excellence (COE), which are affiliated with the Huntington Disease Society of
America (HDSA). The COE provide specialized care for people with HD and the HDSA has
published materials on ADs available to members. Therefore, our sample might include
people more likely to seek and receive information regarding HD. While prevalence of ADs
was lower than expected, our participants might be more likely to have ADs than people
who have not undergone genetic testing, do not have access to a COE, or do not participate
in HD-related research.

Author Manuscript

We cannot exclude the possibility that family members answered items on behalf of
participants, despite instructions that answers should come directly from participants. The
purpose of the HDLIFE study is to develop a HRQOL measure for people with HD; the
examination of factors associated with having ADs was not a primary aim. Therefore, there
are several variables associated with having ADs that we did not measure that have been
found to be associated with ADs, including knowledge of ADs, literacy, self-efficacy,
religiosity, and illness-related fear [20, 23, 26, 36–38].
Despite the 2004 recommendations of the Huntington’s Disease Peer Workgroup, our
findings suggest that prevalence of ADs is low in this population. Interventions designed to
increase patient-provider discussions of ADs are effective in increasing development of and
use of ADs [29]. An important question remains whether health care providers provide
adequate patient education to persons with HD regarding ADs, and at an appropriate level of
literacy. Having ADs is often not considered an important issue in HD until the disease
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symptoms have progressed significantly and the patient and family are considering longterm care placement. Unfortunately, this can result in the patient being unable to voice their
preferences due to advancing dementia [30].

Author Manuscript

There is a recognized need for EOL planning for patients with HD to reduce risk of
emotional distress from unwanted, aggressive and costly EOL care [10, 31]. While we
examined factors associated with having ADs among persons with HD, future studies should
identify patient and health care provider barriers to creation of ADs in this population. Data
from our study could inform development of specific interventions to increase prevalence of
ADs and EOL planning. A promising method involves using vignettes to illustrate diseasespecific EOL scenarios to help patients work through their preferences [32]. This could be
adapted for use in HD by providing patients with scenarios based on common causes of
death in persons with HD. This technique could aid literacy by explaining often
misunderstood medical terms and end-of-life interventions such as cardiopulmonary
resuscitation, feeding tubes, and ventilators [33]. Medicare reimbursement for EOL
discussions is a positive step, although these discussions should begin long before patients
with HD become Medicare eligible. Prevalence of ADs and EOL plans is surprisingly low
considering the severity and long disease course of HD. Health care providers should
actively educate and assist patients with HD in making ADs and EOL plans to specify
treatment preferences while they still have the cognitive ability.
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Computer adaptive tests
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COE

Centers of Excellence

EOL

End of life

HD

Huntington disease

HDQLIFE Huntington Disease Quality of Life study
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HRQOL

Health-related quality of life

PRO

Patient-reported outcome

PROMIS

Patient-Reported Outcomes Measurement Information System

SF

Short form

TFC

Total Functional Capacity scale

TMS

Total motor score

UHDRS

United Huntington Disease Rating Scale
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Table 1.

Author Manuscript

Participant demographics by HD stage
Stage
Prodromal (n=197)

Early (n=193)

42.80

51.98

54.95

49.04

(12.17)

(12.41)

(12.04)

(13.23)

15.91

14.69

14.24

a

15.07

(2.94)

(2.78)

(2.64)

(2.89)

Female

64.0

45.1

41.6

59.2

Male

36.0

54.9

58.4

40.8

White

97.5

96.4

92.9

96.0

Other

2.0

3.6

7.1

3.8

Variable
Age
Mean (SD)
Years of Education
Means (SD)

a

a

Late (n=113)

a

All (n=503)

Gender (%)

Race (%)

Author Manuscript

Ethnicity (%)

Marital Status (%)

a

Unknown

0.5

0.0

0.0

0.2

Not Hispanic or Latino

92.4

92.7

94.3

93.7

Hispanic or Latino

1.5

4.1

0.9

2.4

Not Provided

6.1

3.1

1.8

4.0

Married

67.0

52.8

62.8

60.8

a

= significantly different than prodromal, all p<0.05

Author Manuscript
Author Manuscript
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Table 2.

Author Manuscript

End of life planning by HD stage
HD Stage Frequency Number (%)
Prodromal

Early Stage

Late Stage

Total

I have not thought about getting an advance directive

35 (17.8)

28 (14.5)

14 (12.4)

77 (15.3)

I have thought about getting an advance directive

83 (42.1)

75 (38.9)

22 (19.5)

182 (36)

I have taken steps to obtain an advance directive

20 (10.2)

18 (9.3)

15 (13.3)

53 (10.5)

I have an advance directive

59 (29.9)

72 (37.3)

62 (54.9)

193 (38.2)

197

193

113

503

I have not thought about preparing a living will

30 (15.3)

29 (15.2)

18 (16.1)

78 (15.6)

I have thought about preparing a living will

90 (45.9)

77 (40.3)

22 (19.6)

190 (37.9)

Advance directive

Total
Living will

Author Manuscript

I have taken steps to prepare a living will

18 (9.2)

14 (7.3)

9 (8.0)

41 (8.2)

I have a living will

58 (29.6)

71 (37.2)

63 (56.3)

192 (38.3)

196

193

112

501

I have not thought of getting a healthcare POA

55 (27.9)

32 (16.6)

14 (12.4)

102 (20.2)

I have thought of getting a healthcare POA

71 (36.0)

64 (33.2)

16 (14.2)

152 (30.1)

I have taken steps to identify a healthcare POA

21 (10.7)

19 (9.8)

11 (9.7)

51 (10.1)

I have a healthcare POA

47 (23.9)

70 (36.3)

69 (61.1)

186 (36.8)

194

185

113

492

I have not thought about my preference for resuscitation if I stop breathing

55 (28.1)

49 (25.8)

26 (23.2)

131 (26.2)

I have thought about my preference for resuscitation if I stop breathing

66 (33.7)

60 (31.6)

27 (24.1)

154 (30.8)

I have made my preference for resuscitation clear to others if I stop breathing

75 (38.3)

81 (42.6)

59 (52.7)

215(43)

196

190

112

500

I have not thought about starting a conversation about death with my friends, family,
or members in the community (e.g., church/synagogue)

78 (39.6)

49 (25.4)

48 (42.5)

175 (34.7)

I have thought about starting a conversation about death with my friends, family or
members in the community

27 (13.7)

45 (23.3)

16 (14.2)

186 (36.8)

I have taken steps to start a conversation about death with my friends, family or
members in the community

33 (16.8)

32 (16.6)

11 (9.7)

28 (5.5)

I have had a conversation about death with my friends, family or members in the
community

56 (28.4)

64 (33.2)

37 (32.7)

53 (10.5)

194

190

112

496

I have not thought about where I would like to die

96 (49.5)

85 (45)

48 (42.9)

230 (46.3)

I have thought about where I would like to die

75 (38.7)

77 (40.7)

33 (29.5)

186 (37.4)

I have taken steps to arrange where I would like to die

10 (5.2)

10 (5.3)

8 (7.1)

28 (5.6)

I have identified a location where I would like to die

13 (6.7)

17 (9.0)

23 (20.5)

53 (10.7)

194

189

112

497

Total
Healthcare power of attorney (POA)

Total
Resuscitation preference

Author Manuscript

Total
Conversations about death and dying

Total
Location of death preferences (i.e., at home, in the hospital)

Author Manuscript

Total
Nursing home care
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HD Stage Frequency Number (%)

Author Manuscript

Prodromal

Early Stage

Late Stage

Total

I have not thought about nursing home care

116 (59.2)

93 (48.9)

52 (46)

263 (52.5)

I have thought about nursing home care

61 (31.1)

73 (38.4)

28 (24.8)

162 (32.3)

I have taken steps to arrange nursing home care

13 (6.6)

11 (5.8)

6 (5.3)

30 (6.0)

6(3.1)

13 (6.8)

27 (23.9)

46 (9.2)

196

193

113

501

I have given little or no thought to palliative care

116 (60.4)

101 53.7)

63 (56.8)

282 (57.0)

I have thought about palliative care

69 (35.9)

72 (38.3)

23 (20.7)

164 (33.4)

7 (3.6)

12 (6.4)

7 (6.3)

26 (5.3)

I am receiving palliative care

0 (0)

3 (1.6)

18 (16.2)

21 (4.3)

Total

192

188

111

493

I have not thought about hospice care

119 (61.3)

101(52.9)

65 (57.5)

286 (57.2)

I have thought about hospice care

73 (37.6)

81 (42.4)

42 (37.2)

197 (39.4)

2 (1.0)

9 (4.7)

5 (4.4)

16 (3.2)

0

0

1 (0.9)

1 (0.2)

194

191

113

500

I have established nursing home care
Total
Palliative care

I have taken steps to arrange palliative care

Hospice care

Author Manuscript

I have taken steps to arrange hospice care
I am receiving hospice care
Total

Author Manuscript
Author Manuscript
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Table 3.

Author Manuscript

Bivariate analyses results comparing participants with and without advance directives

Author Manuscript

a

Variable

Statistic

p value

Age

t(503)=−8.632

Gender

X2 (1, n= 505) = 0.63

0.426

Race

X2

(1, n= 504) = 2.48

0.115

Marital status

X2

(1, n= 504) = 3.84

0.050

HD stage

X2

(2, n= 503) = 9.01

<0.001

Years Education

t(501) = −2.89

HDQLIFE Chorea SF

t(490) =−1.66

0.097

HDQLIFE Speech SF

t(499)=−1.51

0.132

HDQLIFE Swallowing SF

t(498)=−2.110

0.035

HDQLIFE Concern for Death & Dying SF

t(491 )=1.943

0.053

HDQLIFE Meaning & Purpose SF

t(493)=−2.915

PROMIS Anxiety SF

t(330)=2.353

a

<0.001

a

a

0.004

a

0.004
0.019

Note: = remains significant after Bonferroni Correction,SF = short form

Author Manuscript
Author Manuscript
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Table 4.

Author Manuscript

Multivariable logistic regression model
Factor

Odds Ratio

95% Confidence Interval

Age

1.06

1.03 , 1.08

Early Stage HD*

1.45

0.76 , 2.76

Late Stage HD*

2.87

1.35 , 6.14

Years of Education

1.12

1.02 , 1.22

HDQLIFE Concern for Death & Dying SF

0.98

0.95 , 1.02

HDQLIFE Meaning & Purpose SF

1.01

0.99 , 1.05

PROMIS Anxiety SF

0.99

0.96 , 1.02

*
Note: Prodromal group is the index group; SF = short form; all p values <0.02.

Author Manuscript
Author Manuscript
Author Manuscript
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